Xu Zhi is an excellent researcher with extraordinary scientific ability. She has been worked on her Ph.D. Degree from April 2004 to March 2008 here. She hopes to find out characteristic alterations of gene expression in endometrial cancer.
Xu Zhi is an excellent researcher with extraordinary scientific ability. She has been worked on her Ph.D. Degree from April 2004 to March 2008 here. She hopes to find out characteristic alterations of gene expression in endometrial cancer.
Авторское право:
Attribution Non-Commercial (BY-NC)
Доступные форматы
Скачайте в формате DOC, PDF, TXT или читайте онлайн в Scribd
Xu Zhi is an excellent researcher with extraordinary scientific ability. She has been worked on her Ph.D. Degree from April 2004 to March 2008 here. She hopes to find out characteristic alterations of gene expression in endometrial cancer.
Авторское право:
Attribution Non-Commercial (BY-NC)
Доступные форматы
Скачайте в формате DOC, PDF, TXT или читайте онлайн в Scribd
recommendation of Dr. Xu Zhi for supporting her application of DOD Breast Cancer Postdoctoral Fellowship Award, as she is an excellent researcher with extraordinary scientific ability.
I am the Professor/Chairman of the Department of
Obstetrics and Gynecology in Osaka City University Graduate School of Medicine, Osaka, Japan. Dr. Zhi graduated from China Medical University in 1999, and then worked as a medical doctor in Beijing, China until she came to our department in Japan. She has been worked on her Ph.D. degree from April 2004 to March 2008 here, and I was deeply impressed by Dr. Zhi’s scientific ability and highly self-motivated research attitude.
During the Ph.D. course, Dr. Zhi has accumulated
abundant experience on gynecological cancer research. She aimed at the molecular mechanisms underlying endometrial cancer, which is the most common malignant tumor of the female genital system in developed countries. She hopes to find out the characteristic alterations of gene expression in endometrial cancer, which could be helpful to elucidate the pathogenic and therapeutic intervention of endometrial cancer. She adopted a rare endometrial cancer cell line (HHUA) expressing the estrogen receptor, and investigated the angiogenesis- and apoptosis-related genes based on quantitative real-time RT-PCR assays. This study showed the characteristic gene expression of VEGF and Bcl-2 and, for the first time revealed the fact that ERα and ERβ expression in HHUA cells was converse to that in normal endometria, which should be taken into consideration to understand the biological particularity of endometrial cancer cells. The results have been published in International Journal of Oncology, 31 (6): 1333-1338, 2007. Dr. Zhi also continued her work on endometrial cancer study to detect gene expression variation under the induction of 17β-estradiol, 4- Hydroxytamoxifen and the pure ER antagonist ICI182,780, as well as to investigate gene mutations of tumor suppressor p53 by DNA sequencing, etc. Other than the in vitro studies, an animal experiment on mouse reproductive hormone receptor expression was published in International Journal of Molecular Medicine, 20 (3): 287- 292, 2007. Dr. Zhi works very effectively, and on the other hand, she is a modest researcher and always cooperates very well with other investigators.
Due to Dr. Xu Zhi’s excellent work, I enthusiastically
hope that the DOD Breast Cancer Postdoctoral Fellowship Award will fund her for her study on breast cancer. I believe that she could make much progress, and could contribute great efforts to breast cancer research.
Sincerely yours,
Osamu Ishiko, M.D. & Ph.D.
Professor/Chairmen of Department of Obstetrics and
Gynecology Osaka City University Graduate School of Medicine 1-4-3 Asahimachi, Abeno-ku, Osaka 545-8585, Japan Tel: +81-6-6645-3862 Fax: +81-6-6646-5800 E-mail: obandg@med.osaka-cu.ac.jp
Walked out of the New Road to Conquer Cancer: Walked out of the New Way of Cancer Treatment with Immune Regulation and Control of Combination of Chinese and Western Medicine